Manifestation of Agranulocytosis in the Oral Cavity (Clinical Case)
Acute agranulocytosis is a rare, potentially life-threatening condition that is associated with taking medications in more than 70 % of cases. Agranulocytosis is characterized by the number of peripheral neutrophils < 0.5 × 109/l. Currently, due to the widespread use of cytotoxic therapy in medical practice, as well as the emergence of a large number of new pharmacological agents, the frequency of cases of agranulocytosis has increased significantly. Although this pathology can be found quite rarely (1 case per 1 200 people), its manifestations in the oral cavity such as ulcerative-necrotic gingivitis and stomatitis, herpetic rashes, necrosis of the tonsils, tooth mobility are a serious problem for a dentist involved in the treatment of this disease. This article will consider a clinical case of acquired agranulocytosis of a young patient against the background of taking thyrostatics, with vivid manifestations of the disease in the oral cavity. Treatment and diagnosis were carried out conscientiously by hematologists, endocrinologists and dentists, based on examination, complaints, careful collection of anamnesis and the results of additional studies. Despite the fact that acquired agranulocytosis is a rather rare disease, the described algorithms of the work carried out, supported by a photoprotocol and the results of treatment, will be relevant for dentists of all specialties, for the formation of clinical thinking and observation.
Kostionova-Ovod I.A., Simanovskaya O.E., Trunin D.A., Postnikov M.A., Mironuk O.A. 2022. Manifestation of Agranulocytosis in the Oral Cavity (Clinical Case). Challenges in Modern Medicine. 45 (3): 273–280 (in Russian). DOI: 10.52575/2687-0940-2022-45-3-273-280
While nobody left any comments to this publication.
You can be first.
Chen W.T., Chi C.C. 2019. Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies. Br. J. Clin. Pharmacol. Sep; 85 (9): 1878–1887. doi: 10.1111/bcp.13989.
Di Fonzo H., Villegas Gutsch M., Castroagudin A., Cabrera M.V., Mazzei M.E., Rueda D. 2018. Agranulocytosis Induced by Vancomycin. Case Report and Literature Review. Am. J. Case. Rep. Sep 3; 19: 1053–1056. doi: 10.12659/AJCR.909956.
Fasullo S., Davì S., Cosenza G., Di Franco F., La Manna N., Giubilato A., Vetrano G., Maringhini G. 2018. Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature. J. Thromb. Thrombolysis. May; 45 (4): 588–592. doi: 10.1007/s11239-018-1624-3.
Garcia Del Campo C., Murcia Soler M., Martinez-Mir I., Palop Larrea V. 2021. Adecuación de la seguridad del metamizol y agranulocitosis [Adequacy of the safety of metamizole and agranulocytosis]. Aten Primaria. Jun-Jul; 53 (6): 102047. Spanish. doi: 10.1016/j.aprim.2021.102047.
Genchanok Y., Tolu S.S., Wang H., Arora S. 2019. Agranulocytosis from Outpatient Antimicrobial Treatment with Ceftriaxone: A Case Report. Perm. J. 2019; 23: 18–190. doi: 10.7812/TPP/18-190.
Gonnert F.A., Meißner W. 2018. Kasuistik: Metamizol-induzierte Agranulozytose [Case Report – Metamizole-Induced Agranulocytosis]. Anasthesiol Intensivmed Notfallmed Schmerzther. May; 53 (5): 388–394 (in German). doi: 10.1055/s-0043-115329.
Kılıç Ö., İşeri Nepesov M., Ulukapı H.B., Özdemir Z.C., Bör Ö., Dinleyici E.Ç. 2021. Paediatric Agranulocytosis Associated with Metamizole Treatment. Paediatr Drugs. Jan; 23 (1): 105–110. doi: 10.1007/s40272-020-00431-1.
Lhomme F., Ochmann M., Lamy T. 2015. Agranulocytose médicamenteuse [Drug-induced agranulocytosis]. Rev Prat. May; 65 (5): 697–700 (in French).
Lopes V., Ramos J., Dias P., Santos A. 2021. Nitrofurantoin-induced agranulocytosis. B.M.J. Case. Rep. Nov 11; 14 (11): e246788. doi: 10.1136/bcr-2021-246788.
McCulloch J.E., Miller A., Borcea M., Reid J. 2021. Austrian syndrome, ceftriaxone-induced agranulocytosis and COVID-19. B.M.J. Case. Rep. Jan 6; 14 (1): e239355. doi: 10.1136/bcr-2020-239355.
Mijovic A., MacCabe J.H. 2020. Clozapine-induced agranulocytosis. Ann. Hematol. Nov; 99 (11): 2477–2482. doi: 10.1007/s00277-020-04215-y.
Patel R., Lima A., Burke C., Hoffman M. 2019. Monocytopenia in clozapine-induced agranulocytosis: insights into pathophysiology and treatment. B.M.J. Case. Rep. Jan 18; 12 (1): bcr-2018-226016. doi: 10.1136/bcr-2018-226016.
Ribé Buitrón J.M., González Rodríguez M., Barceló Colomer M.E. 2021. Clozapina y agranulocitosis: repensando la utilidad de su monitorización [Clozapine and agranulocytosis: Rethinking the usefulness of its monitoring]. Aten Primaria. Oct; 53 (8): 102114 (in Spanish). doi: 10.1016/j.aprim.2021.102114.
Schinz K., Waldfahrer F., Wüst W., Iro H. 2020. Agranulozytose nach Metamizol-Einnahme – ein unterschätztes Risiko? [Agranulocytosis after use of metamizole – an underestimated risk?]. Laryngorhinootologie. Oct; 99 (10): 707–712. (in German). doi: 10.1055/a-1190-4445.
Stern A., Carrara E., Bitterman R., Yahav D., Leibovici L., Paul M. 2019. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. Cochrane Database Syst. Rev. Jan 3; 1 (1): CD012184. doi: 10.1002/14651858.
Thompson R.A., Isin E.M., Ogese M.O., Mettetal J.T., Williams D.P. 2016. Reactive metabolites: current and emerging risk and hazard assessments. Chem. Res. Toxicol. 29 (4): 505–533.
Tunsirimas N., Pariwatcharakul P., Choovanichvong S., Ratta-Apha W. 2019. Clozapine-induced agranulocytosis and leukopenia: Incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand. Asian J. Psychiatr. Mar; 41: 13–16. doi: 10.1016/j.ajp.2019.03.002.
Vicente N., Cardoso L., Barros L., Carrilho F. 2017. Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management. Drugs R. D. Mar; 17 (1): 91–96. doi: 10.1007/s40268-017-0172-1.
Wiciński M., Węclewicz M.M. 2018. Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring. Curr. Opin. Hematol. Jan; 25 (1): 22–28. doi: 10.1097/MOH.0000000000000391
Zhu D., Zhang S., Cao X., Xia Q., Zhang Q., Deng D., Gao S., Yu H., Liu Y., Zhou H., Tao F., Sun X. 2021. Thionamide-induced Agranulocytosis: A Retrospective Analysis of 36 Patients With Hyperthyroidism. Endocr. Pract. Dec; 27 (12): 1183–1188. doi: 10.1016/j.eprac.2021.06.017